Human placental protein 13,PP13 ELISA Kit

Code CSB-E12733h
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
lectin, galactoside-binding, soluble, 13
Alternative Names
GAL 13 ELISA Kit; Gal-13 ELISA Kit; GAL13 ELISA Kit; Galactoside binding soluble lectin 13 ELISA Kit; Galactoside-binding soluble lectin 13 ELISA Kit; Galectin-13 ELISA Kit; Galectin13 ELISA Kit; Lectin galactoside binding soluble 13 ELISA Kit; LGALS 13 ELISA Kit; LGALS13 ELISA Kit; PLAC 8 ELISA Kit; PLAC8 ELISA Kit; Placental protein 13 ELISA Kit; Placental tissue protein 13 ELISA Kit; PP13 ELISA Kit; PP13_HUMAN ELISA Kit
Abbreviation
LGALS13
Uniprot No.
Species
Homo sapiens (Human)
Sample Types
serum, urine, tissue homogenates
Detection Range
3.9 pg/mL-1000 pg/mL
Sensitivity
3.9 pg/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Cell Biology
Assay Principle
quantitative
Measurement
Competitive
Precision
 
Linearity
 
Recovery
 
Typical Data
 
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

This Human LGALS13 ELISA Kit was designed for the quantitative measurement of Human LGALS13 protein in serum, urine, tissue homogenates. It is a Competitive ELISA kit, its detection range is 3.9 pg/mL-1000 pg/mL and the sensitivity is 3.9 pg/mL.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Binds beta-galactoside and lactose. Strong inducer of T-cell apoptosis. Has hemagglutinating activity towards chicken erythrocytes.
Gene References into Functions
  1. Galectin-13 does not bind beta-galactosides and forms dimers via intermolecular disulfide bridges between Cys-136 and Cys-138. PMID: 29343868
  2. First-trimester PP-13 levels are significantly correlated with BMI and smoking. These correlations appear independent of uterine and umbilical artery resistance. In low risk patients, PP-13 levels fail to predict the risk for pre-eclampsia or small for gestational age (SGA) neonates. PMID: 26910737
  3. Gal-3 was significantly downregulated only in the extravillous trophoblast of intrauterine growth restriction ( IUGR) placentas. In contrast, expressions of gal-2 and gal-13 were downregulated in both villous and extravillous trophoblast cells of IUGR placentas. PMID: 27070577
  4. Placental protein 13 was localized to syncytiotrophoblasts in the chorionic villi and to occasional multinucleated luminal trophoblasts within converted decidual spiral arterioles in preeclampsia patients. PMID: 21989657
  5. study provides a basis for replenishing patients at risk for preeclampsia by the full length but not the truncated PP13 PMID: 25079598
  6. inadequate sensitivity as first trimester serum marker for pre-eclampsia PMID: 24786703
  7. As gal-13 with its anti-inflammatory functions plays a role in maternal immune system, a lack of gal-13 may contribute to an imbalance in inflammation processes in the placenta during pregnancy and therefore influences development of gestational diabetes. PMID: 25499680
  8. Evaluation of placental protein 13 (PP13) and risk factors as markers for predicting preeclampsia. PMID: 24607918
  9. Among singletons with severe preeclampsia, levels were significantly reduced, however, among twins, only a non-significant tendency for a reduction was recorded. PMID: 23729534
  10. Data in rats suggest that human LGALS13 plays role in maintaining uteroplacental blood flow and plays possible role in facilitating proper adaptation of maternal vasculature to pregnancy. PMID: 23406577
  11. The maternal serum level of placental protein 13 is significantly lower in Egyptian patients with pre-eclampsia compared to controls. PMID: 22460234
  12. secretion of PAPP-A, ADAM12 and PP13 is closely related to the size of the placenta in the beginning of pregnancy. After 8 weeks of pregnancy, which is the time for luteoplacental shift, the correlation disappears. PMID: 22015022
  13. PP13 is released from the syncytiotrophoblast in preterm preeclampsia and HELLP, mimicked in BeWo cells by ischemic stress, suggesting PP13 is a placental alarmin. PMID: 21596368
  14. ABO blood group can alter PP13-bioavailability in blood PMID: 21799738
  15. PP13 was best in predicting early onset pre-eclampsia with a sensitivity of 79% at a 20% false positive rate. PMID: 21652068
  16. PP13 mRNA is lower in the third trimester at the time of disease while protein level accumulates and become higher creating an unparallel change in the level of the mRNA and the corresponding protein. PMID: 21257080
  17. PP13 levels were decreased in women with preeclampsia. PMID: 21257081
  18. PP13 is a suitable stable molecule and can be treated under routine laboratory and transport temperatures. PMID: 20509161
  19. gene polymorphism is associated with an increased risk of preterm labour PMID: 19818512
  20. multiples of the gestation-specific normal median significantly lower in trisomy 18 and 13 pregnancies PMID: 19844942
  21. level in preeclampsia was significantly lower than that in controls PMID: 19813218
  22. PP13 is implicated in the pathogenesis of impaired placentation and subsequent development of early-preeclampsia but measurement of this placental product is unlikely to be useful in screening for the disease at 11-13 weeks. PMID: 19777530
  23. The primary structure of the newly sequence analysed placental tissue protein 13 (PP13) was highly homologous to several members of the beta-galactoside-binding S-type lectin (galectin) family PMID: 11742106
  24. PP13/galectin-13 may have special haemostatic and immunobiological functions at the lining of the common feto-maternal blood-spaces or developmental role in the placenta. PMID: 15009185
  25. screening of maternal PP13 levels in the first trimester is a promising diagnostic tool for the prediction of preeclampsia with high sensitivity and specificity. PMID: 17618748
  26. Decreased levels of PP13 (placental protein 13) were not significantly correlated with the studied adverse pregnancy outcomes of intrauterine growth restriction, preterm delivery, low birth weight, and intrauterine fetal demise. PMID: 18186153
  27. Maternal serum PP13 concentration in the first trimester was significantly lower in patients who developed preterm and early-onset preeclampsia than in those with normal pregnancies. PMID: 18539259
  28. parallel to its decreased placental expression, an augmented membrane shedding of PP13 contributes to the increased third trimester maternal serum PP13 concentrations in women with preterm pre-eclampsia and HELLP syndrome. PMID: 18791734
  29. findings indicate that an alteration in the placental protein 13 (PP13) messenger RNA expression in the trophoblasts may be associated with the pathogenesis of preeclampsia PMID: 19087972

Show More

Hide All

Subcellular Location
Cytoplasm. Nucleus matrix.
Tissue Specificity
Detected in adult and fetal spleen, fetal kidney, adult urinary bladder and placenta. Placental expression originates predominantly from the syncytiotrophoblast.
Database Links

HGNC: 15449

OMIM: 608717

KEGG: hsa:29124

STRING: 9606.ENSP00000221797

UniGene: Hs.23671

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1